US biotechnology company ACROBiosystems on Thursday unveiled its latest innovation portfolio, featuring ACRO AIx, CHO-Direct and GlobalLifeShip cross border supply chain to respond the demands of the AI-driven drug discovery era.

CHO-Direct Rapid High-Throughput Affinity Validation Service and ACRO AIx expand ACROBiosystems' portfolio of products and experimental validation capabilities for AI-driven drug discovery. CHO-Direct is designed to provide a rapid entry point for candidate validation, delivering affinity data for antibodies in as little as four days from sequence submission. ACRO AIx brings together standardised products, reproducible validation modules, and experimental tools to build wet-lab infrastructure for AI-enabled research across the industry. As one of its core applications, CHO-Direct connects with R&D workflows through open interfaces.

Capabilities of ACROBiosystems' GlobalLifeShip cross border supply chain include cross-border transportation, overseas warehousing, and last-mile delivery. Drawing on ACROBiosystems' supply chain and global hubs built through serving life science customers worldwide, the platform supports partners in entering and serving international markets, complementing the company's research products and experimental validation capabilities.